4 results on '"Pauwels, M"'
Search Results
2. Peroxisomes in mice fed a diet supplemented with low doses of fish oil.
- Author
-
Branden, C., Craemer, D., Pauwels, M., and Vamecq, J.
- Abstract
The influence of low dietary doses (0.1 and 0.8% w/w) of a commercial fish oil preparation on peroxisomes in normal mice was studied and compared to the known strong inductive effects of high (10%) fish oil diets. Low fish oil doses were chosen to supply the mice with a concentration of docosahexaenoic acid, which was beneficial to patients with a peroxisomal disease. Peroxisomes were evaluated by cytochemical, morphometric, and enzymological techniques. The 0.1% fish oil diet had no effect on peroxisomes in liver, heart, and kidney even after prolonged treatment. The 0.8% diet did not change the peroxisomal number nor the catalase (EC 1.11.1.6) activity in the liver. Hepatic peroxisomal β-oxidation, however, was increased by 50% after 14 d. This was accompanied by reduced peroxisomal size. The 0.8% diet also caused a small increase (+25%) in myocardial catalase activity. No effect was observed in kidneys. Our results indicate that in mice a low (<0.8%) dietary fish oil dose has no or only a slight effect on hepatic peroxisomal β-oxidation. This may be of particular interest to patients with a peroxisomal fatty acid β-oxidation defect and who display a severe deficiency of docosahexaenoic acid-diets supplemented with low fish oil doses will improve the docosahexaenoic acid level without adding a strong load to the disturbed fatty acid metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 1995
- Full Text
- View/download PDF
3. Peroxisome-proliferating effects of fenoprofen in mice.
- Author
-
De Craemer D, Van den Branden C, Pauwels M, and Vamecq J
- Subjects
- Animals, Body Weight drug effects, Carnitine Acyltransferases metabolism, Liver enzymology, Liver ultrastructure, Male, Mice, Mice, Inbred Strains, Microbodies enzymology, Microbodies ultrastructure, Organ Size drug effects, Oxidoreductases metabolism, Palmitoyl-CoA Hydrolase metabolism, Time Factors, Cyclooxygenase Inhibitors pharmacology, Fenoprofen pharmacology, Liver drug effects, Microbodies drug effects
- Abstract
We report on hepatic effects obtained in vivo by treating mice with different doses of fenoprofen, an arylpropionic acid previously shown to inhibit in vitro peroxisomal very long chain fatty acid oxidation. A strong and dose-related induction of peroxisomal palmitoyl-CoA oxidase, and of carnitine acyltransferase and acyl-CoA hydrolase activities was recorded in liver homogenates of mice fed diets supplemented with different contents [0.01, 0.05, 0.1, or 1% (w/w)] of fenoprofen for 6 d. Peroxisomal glycolate oxidase and mitochondrial butyryl-CoA, octanoyl-CoA, and palmitoyl-CoA dehydrogenases were unaffected or increased. Hepatic catalase activity was significantly increased in mice fed the diet with 0.05 and 0.1% fenoprofen but, surprisingly, was not stimulated in mice fed the 1% fenoprofen-containing diet. A time-related but unequal induction of acyl-CoA oxidases and catalase was observed with the 0.1% fenoprofen diet: at 21 d of treatment, the induction of lignoceroyl-CoA and palmitoyl-CoA oxidase activities were five-fold stronger than that of catalase activity. In mice treated with 1% fenoprofen for up to 6 d, only acyl-CoA oxidase activities were found to be significantly increased. Morphometric analysis of the liver peroxisomes in mice treated with 0.1% fenoprofen evidenced an increase in size, volume density, and surface density along with a reduced ratio between perimeter and area of the peroxisomal profiles. No morphological marker for very long chain fatty acid deposition could be detected in livers from fenoprofen-treated animals. Our findings clearly demonstrate that fenoprofen acts as a peroxisome proliferator in the liver of mice and do not support the occurrence of in vivo reduction of very long chain fatty acid oxidation in liver from treated animals.
- Published
- 1998
4. Dietary docosahexaenoic acid has little effect on peroxisomes in healthy mice.
- Author
-
De Craemer D, Pauwels M, and Van den Branden C
- Subjects
- Acyl-CoA Oxidase, Animals, Catalase biosynthesis, Enzyme Induction drug effects, Heart drug effects, Hydrogen Peroxide metabolism, Kidney drug effects, Kidney enzymology, Liver drug effects, Liver enzymology, Male, Mice, Microbodies metabolism, Microbodies ultrastructure, Myocardium enzymology, Oxidoreductases metabolism, Peroxisomal Disorders diet therapy, Peroxisomal Disorders enzymology, Time Factors, Urate Oxidase metabolism, Dietary Fats, Unsaturated administration & dosage, Docosahexaenoic Acids administration & dosage, Microbodies drug effects
- Abstract
NMRI mice were fed diets supplemented with 0.05, 0.2, or 2% (w/w) docosahexaenoic acid (DHA), a polyunsaturated fatty acid present in fish oil, for 3 d, 3 wk, or 3 mon. The doses of DHA were chosen to supply the mice with concentrations of DHA which approximate those that have been reported to be beneficial to patients with peroxisomal disease. Diets containing 0.05 or 0.2% DHA did not change hepatic, myocardial, and renal catalase (EC 1.11.1.6) activity except for a slight but significant increase (to 120%) in myocardial catalase activity in mice treated with the 0.05% DHA diet for 3 mon. A diet with 2% DHA induced myocardial catalase activity to 150% after both 3 d and 3 wk of administration. In the liver of mice fed this diet for 3 wk, hepatic catalase activity was increased to 140% while no induction of palmitoyl-CoA oxidase (EC 1.3.99.3), urate oxidase (EC 1.7.3.3), and L-alpha-hydroxyisovalerate oxidase (EC 1.1.3.a) was observed. With the light microscope, no changes in peroxisomal morphology were visually evaluated in catalase stained sections of liver, myocardium, and kidney of mice fed either diet. Our results show that in healthy mice a low dietary DHA dose (< 0.2%; this corresponds to a dose prescribed to peroxisomal patients) has no effect on several hepatic peroxisomal H2O2-producing enzymes, including the rate-limiting enzyme of the peroxisomal fatty acid beta-oxidation. This may indicate that such a DHA dose will not add a strong load on the often disturbed fatty acid metabolism in the liver of patients with peroxisomal disorders.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.